+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Targeted SSTR Radionuclide Drug Conjugates Market - Global Forecast 2026-2032- Product Image
Targeted SSTR Radionuclide Drug Conjugates Market - Global Forecast 2026-2032- Product Image
Sale

Targeted SSTR Radionuclide Drug Conjugates Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6082278
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Targeted SSTR Radionuclide Drug Conjugates Market is projected to reach USD 858.47 Million in 2026. It is expected to continue growing at a CAGR of 7.42%, reaching USD 1.32 Billion by 2032.

Targeted SSTR Radionuclide Drug Conjugates: Executive Overview

Targeted SSTR radionuclide drug conjugates are radiopharmaceuticals designed to bind somatostatin receptors, particularly SSTR2, and deliver therapeutic radionuclides to receptor-expressing cells. Their development is closely linked to neuroendocrine tumors, where receptor imaging and peptide-based targeting can support patient selection and treatment planning. The field combines molecular targeting, nuclear medicine, diagnostic imaging, radiation safety, and specialized manufacturing.

Theranostics and Precision Delivery Are Reshaping the Field

The landscape is shifting toward theranostic care pathways that connect receptor imaging with targeted radionuclide treatment. Progress depends on improving radionuclide availability, peptide stability, dosimetry, patient monitoring, and treatment-center capability. Regulatory expectations, radiation-protection requirements, isotope logistics, and the need for coordinated multidisciplinary care remain important determinants of clinical adoption.

Artificial Intelligence Strengthens Selection, Dosimetry, and Operations

Artificial intelligence can support this field by improving image interpretation, quantifying SSTR expression, segmenting tumors and organs, and assisting individualized dosimetry. It may also help identify treatment-response patterns, optimize scheduling, detect imaging artifacts, and coordinate isotope logistics. These applications require representative clinical data, transparent validation, regulatory oversight, and safeguards against biased or non-reproducible decisions.

Regional Dynamics Reflect Uneven Access to Isotopes and Specialized Care

North America combines advanced nuclear-medicine infrastructure, clinical research capacity, and established regulatory pathways, while Latin America is shaped by uneven access to PET and radionuclide-treatment facilities, specialist training, and isotope distribution. Europe benefits from strong academic networks and coordinated healthcare systems, although national reimbursement and regulatory processes differ. The Middle East is developing specialized oncology and nuclear-medicine capacity, with access concentrated in major medical centers. Africa faces broader constraints in isotope supply, equipment, workforce, and referral systems. Asia-Pacific includes highly capable centers in Australia, Japan, South Korea, China, and Singapore alongside markets where infrastructure and trained personnel remain limited.

Economic and Security Groupings Highlight Cooperation Opportunities

ASEAN countries can benefit from shared training, regional referral networks, and coordinated isotope logistics. BRICS members present diverse capabilities spanning research, manufacturing, clinical delivery, and large patient populations, but regulatory alignment remains uneven. The European Union can leverage cross-border research and technical standards while addressing national differences in reimbursement and service availability. G7 economies generally possess advanced research and healthcare infrastructure, creating opportunities for harmonized evidence generation. GCC states are expanding specialized healthcare capacity, although isotope access and workforce depth vary. NATO members may benefit from resilient medical-supply planning and shared technical expertise, particularly for critical isotope and radiopharmacy infrastructure.

Country-Level Priorities Range from Infrastructure Expansion to Evidence Generation

Australia has strong nuclear-medicine expertise but must manage geographic concentration of specialist services. Brazil and Mexico face opportunities to expand access beyond major urban centers. Canada and the United States have substantial clinical and research capabilities, with continued attention needed for isotope supply, reimbursement, and equitable access. China and India are building capabilities at scale while navigating regulatory, manufacturing, and workforce requirements. Japan and South Korea have advanced nuclear-medicine ecosystems and can contribute to protocol standardization. France, Germany, Italy, Spain, and the United Kingdom combine specialist expertise with differing health-system and reimbursement frameworks. Russia retains nuclear and medical research capabilities, while access, collaboration, and supply-chain conditions influence implementation.

Industry Leaders Should Build Integrated, Evidence-Based Delivery Models

Leaders should secure diversified radionuclide and peptide supply, invest in validated radiopharmacy and radiation-safety systems, and establish partnerships with hospitals capable of imaging, dosimetry, administration, and follow-up. Clinical programs should prioritize clearly defined SSTR-positive populations, standardized endpoints, long-term safety monitoring, and health-economic evidence. Organizations should also develop AI governance frameworks, train multidisciplinary teams, and design access strategies for regions where specialist services are concentrated.

Methodology: Structured Synthesis of Clinical, Technical, and Geographic Evidence

This executive summary uses a qualitative synthesis framework focused on the characteristics of targeted SSTR radionuclide drug conjugates and the operating conditions surrounding their development and use. The assessment considers receptor biology, theranostic workflows, radionuclide production and distribution, clinical infrastructure, regulatory and safety requirements, artificial-intelligence applications, and geographic readiness. Regional, group, and country observations are presented as contextual insights rather than quantified market measurements, and conclusions should be validated against current clinical, regulatory, and institutional sources.

The Field’s Progress Depends on Coordinated Precision Oncology Infrastructure

Targeted SSTR radionuclide drug conjugates sit at the intersection of molecular diagnosis, precision therapy, nuclear medicine, and complex supply chains. Sustainable progress will depend not only on therapeutic innovation but also on reliable isotope access, standardized dosimetry, qualified personnel, evidence-based patient selection, and equitable referral pathways. Organizations that integrate these capabilities while maintaining rigorous safety, data, and regulatory practices will be better positioned to translate scientific advances into dependable clinical care.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Targeted SSTR Radionuclide Drug Conjugates Market, by Radiometal Type
7.1. Introduction
7.2. Actinium 225
7.3. Lutetium 177
7.4. Yttrium 90
8. Targeted SSTR Radionuclide Drug Conjugates Market, by Peptide Analog
8.1. Introduction
8.2. Dotanoc
8.3. Dotatate
8.4. Dotatoc
9. Targeted SSTR Radionuclide Drug Conjugates Market, by Treatment Indication
9.1. Introduction
9.2. Neuroendocrine Tumors
9.3. Thyroid Cancer
10. Targeted SSTR Radionuclide Drug Conjugates Market, by Clinical Phase
10.1. Introduction
10.2. Commercial
10.3. Phase I
10.4. Phase II
10.5. Phase III
10.6. Preclinical
11. Targeted SSTR Radionuclide Drug Conjugates Market, by End User
11.1. Introduction
11.2. Hospital
11.3. Research Institutes
11.4. Specialty Clinics
12. Targeted SSTR Radionuclide Drug Conjugates Market, by Distribution Channel
12.1. Introduction
12.2. Direct Procurement
12.3. Distributor Sales
12.4. Tender
13. Targeted SSTR Radionuclide Drug Conjugates Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Targeted SSTR Radionuclide Drug Conjugates Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Targeted SSTR Radionuclide Drug Conjugates Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Actinium Pharmaceuticals, Inc.
17.2. ACUITY Pharmaceuticals, Inc.
17.3. Bayer AG
17.4. Cardinal Health, Inc.
17.5. Curium Pharma GmbH
17.6. Eckert & Ziegler Radiopharma GmbH
17.7. GE Healthcare Limited
17.8. Ipsen SA
17.9. Isoray Medical, Inc.
17.10. ITM Isotope Technologies Munich SE
17.11. Jubilant Life Sciences Limited
17.12. Lantheus Holdings, Inc.
17.13. Novartis AG
17.14. Point Biopharma Inc.
17.15. PSMA Therapeutics LLC
17.16. RadioMedix, Inc.
17.17. RayzeBio, Inc.
17.18. Sorrento Therapeutics, Inc.
17.19. Telix Pharmaceuticals Limited
17.20. Theragnostics, Inc.
17.21. Viamet Pharmaceuticals, Inc.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Targeted SSTR Radionuclide Drug Conjugates Market, Years Considered for the Study
FIGURE 2. Global Targeted SSTR Radionuclide Drug Conjugates Market, Research Design
FIGURE 3. Global Targeted SSTR Radionuclide Drug Conjugates Market, Research Framework
FIGURE 4. Global Targeted SSTR Radionuclide Drug Conjugates Market, Data Triangulation
FIGURE 5. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2025 vs 2032 (%)
FIGURE 7. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2025 vs 2032 (%)
FIGURE 9. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2025 vs 2032 (%)
FIGURE 11. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2025 vs 2032 (%)
FIGURE 13. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 17. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Targeted SSTR Radionuclide Drug Conjugates Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Targeted SSTR Radionuclide Drug Conjugates Market Segmentation & Coverage
TABLE 2. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 3. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 4. Global Actinium 225 Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Actinium 225 Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Actinium 225 Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Lutetium 177 Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Lutetium 177 Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Lutetium 177 Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Yttrium 90 Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Yttrium 90 Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Yttrium 90 Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 14. Global Dotanoc Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Dotanoc Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Dotanoc Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Dotatate Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Dotatate Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Dotatate Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Dotatoc Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Dotatoc Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Dotatoc Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 24. Global Neuroendocrine Tumors Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Neuroendocrine Tumors Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Neuroendocrine Tumors Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Thyroid Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Thyroid Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Thyroid Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 31. Global Commercial Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Commercial Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Commercial Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Phase I Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Phase I Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Phase I Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Phase II Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Phase II Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Phase II Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Phase III Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Phase III Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Phase III Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Preclinical Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Preclinical Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Preclinical Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 47. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 57. Global Direct Procurement Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Direct Procurement Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Direct Procurement Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Distributor Sales Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Distributor Sales Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Distributor Sales Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Tender Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Tender Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Tender Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Targeted SSTR Radionuclide Drug Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 74. North America Targeted SSTR Radionuclide Drug Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. North America Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 76. North America Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 77. North America Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 78. North America Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 79. North America Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 80. North America Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 81. Latin America Targeted SSTR Radionuclide Drug Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Latin America Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 83. Latin America Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 84. Latin America Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 85. Latin America Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 86. Latin America Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 87. Latin America Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 88. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 90. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 91. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 92. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 93. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 94. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 95. Middle East Targeted SSTR Radionuclide Drug Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Middle East Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 97. Middle East Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 98. Middle East Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 99. Middle East Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 100. Middle East Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 101. Middle East Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 102. Africa Targeted SSTR Radionuclide Drug Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Africa Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 104. Africa Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 105. Africa Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 106. Africa Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 107. Africa Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 108. Africa Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 109. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. ASEAN Targeted SSTR Radionuclide Drug Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. ASEAN Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 112. ASEAN Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 113. ASEAN Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 114. ASEAN Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 115. ASEAN Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 116. ASEAN Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. GCC Targeted SSTR Radionuclide Drug Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. GCC Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 119. GCC Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 120. GCC Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 121. GCC Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 122. GCC Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 123. GCC Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 124. European Union Targeted SSTR Radionuclide Drug Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 125. European Union Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 126. European Union Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 127. European Union Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 128. European Union Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 129. European Union Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. European Union Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 131. BRICS Targeted SSTR Radionuclide Drug Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 132. BRICS Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 133. BRICS Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 134. BRICS Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 135. BRICS Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 136. BRICS Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 137. BRICS Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 138. G7 Targeted SSTR Radionuclide Drug Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. G7 Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 140. G7 Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 141. G7 Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 142. G7 Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 143. G7 Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 144. G7 Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 145. NATO Targeted SSTR Radionuclide Drug Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 146. NATO Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 147. NATO Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 148. NATO Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 149. NATO Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 150. NATO Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. NATO Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 152. Global Targeted SSTR Radionuclide Drug Conjugates Market Size, by Country, 2017-2032 (USD Million)
TABLE 153. United States Targeted SSTR Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 154. United States Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 155. United States Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 156. United States Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 157. United States Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 158. United States Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 159. United States Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 160. Canada Targeted SSTR Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 161. Canada Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 162. Canada Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 163. Canada Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 164. Canada Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 165. Canada Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 166. Canada Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 167. Mexico Targeted SSTR Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 168. Mexico Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 169. Mexico Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 170. Mexico Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 171. Mexico Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 172. Mexico Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 173. Mexico Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 174. Brazil Targeted SSTR Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 175. Brazil Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 176. Brazil Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 177. Brazil Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 178. Brazil Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 179. Brazil Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 180. Brazil Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 181. United Kingdom Targeted SSTR Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 182. United Kingdom Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 183. United Kingdom Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 184. United Kingdom Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 185. United Kingdom Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 186. United Kingdom Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. United Kingdom Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 188. Germany Targeted SSTR Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 189. Germany Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 190. Germany Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 191. Germany Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 192. Germany Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 193. Germany Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 194. Germany Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 195. France Targeted SSTR Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 196. France Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 197. France Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 198. France Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 199. France Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 200. France Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 201. France Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. Russia Targeted SSTR Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 203. Russia Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 204. Russia Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 205. Russia Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 206. Russia Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 207. Russia Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. Russia Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 209. Italy Targeted SSTR Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 210. Italy Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 211. Italy Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 212. Italy Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 213. Italy Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 214. Italy Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 215. Italy Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 216. Spain Targeted SSTR Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 217. Spain Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 218. Spain Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 219. Spain Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 220. Spain Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 221. Spain Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 222. Spain Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 223. China Targeted SSTR Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 224. China Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 225. China Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 226. China Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 227. China Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 228. China Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 229. China Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 230. India Targeted SSTR Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 231. India Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 232. India Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 233. India Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 234. India Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 235. India Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 236. India Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 237. Japan Targeted SSTR Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 238. Japan Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 239. Japan Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 240. Japan Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 241. Japan Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 242. Japan Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 243. Japan Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 244. Australia Targeted SSTR Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 245. Australia Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 246. Australia Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 247. Australia Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 248. Australia Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 249. Australia Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 250. Australia Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 251. South Korea Targeted SSTR Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 252. South Korea Targeted SSTR Radionuclide Drug Conjugates Market Size, by Radiometal Type, 2017-2032 (USD Million)
TABLE 253. South Korea Targeted SSTR Radionuclide Drug Conjugates Market Size, by Peptide Analog, 2017-2032 (USD Million)
TABLE 254. South Korea Targeted SSTR Radionuclide Drug Conjugates Market Size, by Treatment Indication, 2017-2032 (USD Million)
TABLE 255. South Korea Targeted SSTR Radionuclide Drug Conjugates Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 256. South Korea Targeted SSTR Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 257. South Korea Targeted SSTR Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 258. Global Targeted SSTR Radionuclide Drug Conjugates Market Share, by Key Player, 2025
TABLE 259. Global Targeted SSTR Radionuclide Drug Conjugates Market, Key Experts

Companies Mentioned

  • Actinium Pharmaceuticals, Inc.
  • ACUITY Pharmaceuticals, Inc.
  • Bayer AG
  • Cardinal Health, Inc.
  • Curium Pharma GmbH
  • Eckert & Ziegler Radiopharma GmbH
  • GE Healthcare Limited
  • Ipsen SA
  • Isoray Medical, Inc.
  • ITM Isotope Technologies Munich SE
  • Jubilant Life Sciences Limited
  • Lantheus Holdings, Inc.
  • Novartis AG
  • Point Biopharma Inc.
  • PSMA Therapeutics LLC
  • RadioMedix, Inc.
  • RayzeBio, Inc.
  • Sorrento Therapeutics, Inc.
  • Telix Pharmaceuticals Limited
  • Theragnostics, Inc.
  • Viamet Pharmaceuticals, Inc.

Related Topics

Related Reports

Radioligand Therapeutics in Cancer Treatment: Global Markets - Product Image

Radioligand Therapeutics in Cancer Treatment: Global Markets

  • Report
  • 106 Pages
  • Global
From
Gastrointestinal Neuroendocrine Tumors - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Gastrointestinal Neuroendocrine Tumors - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Peptide-Radionuclide Conjugates Market - Global Forecast 2026-2032 - Product Image

Peptide-Radionuclide Conjugates Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide Tetraxetan, (Lu-177)- PNT2002, Radium-223 dichloride), Target (PSMA, SSTR, Bone Metastases), Indication (Prostate Cancer, Neuroendocrine Tumors (NETS), SCLC) - Global Forecast to 2035 - Product Image

Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide Tetraxetan, (Lu-177)- PNT2002, Radium-223 dichloride), Target (PSMA, SSTR, Bone Metastases), Indication (Prostate Cancer, Neuroendocrine Tumors (NETS), SCLC) - Global Forecast to 2035

  • Report
  • 313 Pages
  • Global
From
Lutetium-177 Market - Global Forecast 2026-2032 - Product Image

Lutetium-177 Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.